BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Huang XJ, Yin M, Zhou BQ, Tan XY, Xia YQ, Qin CX. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors. World J Hepatol 2023; 15(8): 985-1000 [PMID: 37701916 DOI: 10.4254/wjh.v15.i8.985]
URL: https://www.wjgnet.com/1007-9327/full/v15/i8/985.htm
Number Citing Articles
1
Shouxing Yang, Jing Xu. Elevated small dense low‐density lipoprotein cholesterol to high‐density lipoprotein cholesterol ratio is associated with an increased risk of metabolic dysfunction associated fatty liver disease in Chinese patients with type 2 diabetes mellitusJournal of Diabetes Investigation 2024; 15(5): 634 doi: 10.1111/jdi.14148
2
Aldo Rocca, Klara Komici, Maria Chiara Brunese, Giulia Pacella, Pasquale Avella, Chiara Di Benedetto, Corrado Caiazzo, Marcello Zappia, Luca Brunese, Gianfranco Vallone. Quantitative ultrasound (QUS) in the evaluation of liver steatosis: data reliability in different respiratory phases and body positionsLa radiologia medica 2024; 129(4): 549 doi: 10.1007/s11547-024-01786-y
3
Amedeo Lonardo. Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative reviewMetabolism and Target Organ Damage 2024; 4(2) doi: 10.20517/mtod.2024.07
4
Grazia Pennisi, Giuseppe Infantino, Ciro Celsa, Gabriele Di Maria, Marco Enea, Marco Vaccaro, Roberto Cannella, Carlo Ciccioli, Claudia La Mantia, Alessandro Mantovani, Francesco Mercurio, Herbert Tilg, Giovanni Targher, Vito Di Marco, Calogero Cammà, Salvatore Petta. Clinical outcomes of MAFLD versus NAFLD: A meta‐analysis of observational studiesLiver International 2024;  doi: 10.1111/liv.16075